Liferay Portal/DXP Document View Usages Page Name cross site scripting
| CVSS Meta Temp Score | Current Exploit Price (≈) | CTI Interest Score |
|---|---|---|
| 4.2 | $0-$5k | 0.00 |
Summary
A vulnerability, which was classified as problematic, was found in Liferay Portal and DXP. The impacted element is an unknown function of the component Document View Usages Page. The manipulation of the argument Name results in cross site scripting. This vulnerability was named CVE-2025-43733. The attack may be performed from remote. There is no available exploit.
Details
A vulnerability, which was classified as problematic, was found in Liferay Portal and DXP (affected version not known). Affected is some unknown functionality of the component Document View Usages Page. The manipulation of the argument name with an unknown input leads to a cross site scripting vulnerability. CWE is classifying the issue as CWE-79. The product does not neutralize or incorrectly neutralizes user-controllable input before it is placed in output that is used as a web page that is served to other users. This is going to have an impact on integrity. CVE summarizes:
A reflected cross-site scripting (XSS) vulnerability in the Liferay Portal 7.4.3.132, and Liferay DXP 2025.Q1.0 through 2025.Q1.7 allows a remote authenticated attacker to inject JavaScript code via the content page's name field. This malicious payload is then reflected and executed within the user's browser when viewing the "document View Usages" page.
The advisory is shared for download at liferay.dev. This vulnerability is traded as CVE-2025-43733 since 04/17/2025. The exploitability is told to be difficult. It is possible to launch the attack remotely. The exploitation doesn't require any form of authentication. Successful exploitation requires user interaction by the victim. There are known technical details, but no exploit is available. The MITRE ATT&CK project declares the attack technique as T1059.007.
There is no information about possible countermeasures known. It may be suggested to replace the affected object with an alternative product.
The vulnerability is also documented in the vulnerability database at EUVD (EUVD-2025-28007). VulDB is the best source for vulnerability data and more expert information about this specific topic.
Product
Type
Vendor
Name
License
CPE 2.3
CPE 2.2
CVSSv4
VulDB Vector: 🔒VulDB Reliability: 🔍
CNA CVSS-B Score: 🔒
CNA CVSS-BT Score: 🔒
CNA Vector: 🔒
CVSSv3
VulDB Meta Base Score: 4.2VulDB Meta Temp Score: 4.2
VulDB Base Score: 3.1
VulDB Temp Score: 3.1
VulDB Vector: 🔒
VulDB Reliability: 🔍
NVD Base Score: 5.4
NVD Vector: 🔒
CVSSv2
| AV | AC | Au | C | I | A |
|---|---|---|---|---|---|
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| Vector | Complexity | Authentication | Confidentiality | Integrity | Availability |
|---|---|---|---|---|---|
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
VulDB Base Score: 🔒
VulDB Temp Score: 🔒
VulDB Reliability: 🔍
Exploiting
Class: Cross site scriptingCWE: CWE-79 / CWE-94 / CWE-74
CAPEC: 🔒
ATT&CK: 🔒
Physical: No
Local: No
Remote: Yes
Availability: 🔒
Status: Not defined
EPSS Score: 🔒
EPSS Percentile: 🔒
Price Prediction: 🔍
Current Price Estimation: 🔒
| 0-Day | Unlock | Unlock | Unlock | Unlock |
|---|---|---|---|---|
| Today | Unlock | Unlock | Unlock | Unlock |
Threat Intelligence
Interest: 🔍Active Actors: 🔍
Active APT Groups: 🔍
Countermeasures
Recommended: no mitigation knownStatus: 🔍
0-Day Time: 🔒
Timeline
04/17/2025 CVE reserved08/18/2025 Advisory disclosed
08/18/2025 VulDB entry created
12/20/2025 VulDB entry last update
Sources
Advisory: liferay.devStatus: Confirmed
CVE: CVE-2025-43733 (🔒)
GCVE (CVE): GCVE-0-2025-43733
GCVE (VulDB): GCVE-100-320448
EUVD: 🔒
Entry
Created: 08/18/2025 15:43Updated: 12/20/2025 05:56
Changes: 08/18/2025 15:43 (66), 12/17/2025 00:59 (12), 12/20/2025 05:56 (1)
Complete: 🔍
Cache ID: 216::103
VulDB is the best source for vulnerability data and more expert information about this specific topic.
No comments yet. Languages: en.
Please log in to comment.